CinDome Pharma, a subsidiary of CinRx Pharma, has secured a $40 million extension to its Series B financing, raising the total to $59 million. This funding will support the ongoing development of deudomperidone (CIN-102), a novel treatment for chronic gastroparesis. Gastroparesis affects millions of individuals in the US and currently lacks a long-term treatment option approved by the FDA. Deudomperidone is based on deuterated domperidone, a commonly prescribed therapy outside the US. It has been engineered to enhance efficacy and reduce the risk of cardiac issues. Clinical trials have shown deudomperidone to be well-tolerated and have demonstrated its potential to improve symptoms. CinDome aims to advance this therapy into late-stage trials to address the significant unmet need in gastroparesis.
Source link: http://www.businesswire.com/news/home/20240516063766/en/CinDome-Pharma-Announces-40-Million-Series-B-Extension
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
